FDA Milestone: 75th Biosimilar Medication Is Approved!
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Exciting Announcement!
The FDA has reached another milestone with the approval of its 75th biosimilar medication!
This achievement represents a major step forward in ensuring more patients have access to critical, life-saving treatments without compromising on quality or safety.
Learn more about biosimilars”
According to the FDA, a biosimilar is a biological product that closely resembles an already FDA-approved reference product and shows no clinically significant differences in safety or effectiveness.
Biosimilars are approved for use across a wide range of diseases, from Crohn’s disease to HER2-positive breast cancer.
For example, Zarxio can serve as an alternative to Neupogen (filgrastim), while the newly approved Avsola is intended to replace Remicade (infliximab) for various autoimmune conditions.
One key advantage of these drugs is that they maintain high standards of safety, efficacy, and quality, while also providing more cost-effective treatment options.
Thus, biosimilar products approved by FDA must also meet requirements mentioned in Biologics Price Competition and Innovation Act.

More on the latest FDA Approvals featured in Hemostasis Today.
-
Feb 25, 2026, 09:14Nominations are Open for 2027 Committee and Leadership Positions – ASH
-
Feb 25, 2026, 09:08Bastu Odoka: Closing the Gap on Anti-D Prophylaxis in Maternal Care
-
Feb 25, 2026, 08:53Eiman Alzaabi: Sharing Rare Observations and Challenging Assumptions in Transfusion Medicine
-
Feb 25, 2026, 08:40Matthew Flick։ A Great Gordon Research Conference on Plasminogen Activation and Extracellular Proteolysis
-
Feb 24, 2026, 16:18Salmaan Dalvi: Mapping Rare Diseases Across East and Central Africa
-
Feb 24, 2026, 16:16Wolfgang Miesbach: Game‑Changing Data on Intensive FVIII Replacement in Haemophilia A with Hypertrophic Synovium
-
Feb 24, 2026, 16:01Is It Safe to Briefly Stop Anticoagulation After VTE? – RPTH Journal
-
Feb 24, 2026, 15:58Anastasia Conti: Honored to Receive the Roche Foundation Grant for Independent Research in Onco-Hematology
-
Feb 24, 2026, 15:55Courtney Lawrence: Targeted Donor Screening Reduces Transfusion-Transmitted Babesia Cases